Eine randomisierte, kontrollierte klinische Studie zur Bewertung der Wirksamkeit von maßgeschneiderten Patienteninformationen und freiwilliger, patientengesteuerter ambulanter digitaler Nachsorge (I-POD) als Ergänzung zur Standardbehandlung gemäß nationaler Leitlinien bei NTP bei erwachsenen Traumapatienten in Norwegen. (POSTRAUMA)
Eine randomisierte kontrollierte klinische Studie zur Bewertung der Wirksamkeit von maßgeschneiderten Patient:inneninformationen und freiwilliger, von Patient:innen verwalteter ambulanter digitaler Nachsorge als Ergänzung zur Standardbehandlung gemäß nationaler Leitlinien bei erwachsenen Trauma-Patient:innen in Norwegen (Die POSTRAUMA-Studie).
The POSTRAUMA trial is a clinical trial at The Regional trauma centre of Western Norway, Haukeland University Hospital.
Trauma is the leading cause of death worldwide in patients aged 1-45 years. In Norway, approximately 10,000 patients are admitted to hospital annually due to trauma, with 66% being male. The mean age is 43 years for male and 48 years for female, indicating a relatively young patient population.
While mortality rates are decreasing, a significant proportion of trauma survivors experience long-term disabilities, reduced quality of life, and difficulties in returning to work. These consequences impose substantial burdens on individuals, families, and society. Considering these issues, a shift in focus is needed-from survival alone to long-term functional recovery and quality of life after trauma.
Severe trauma often requires long-term follow-up, both physically and psychosocially. Traditional follow-up can be fragmented and not tailored to individual needs. Digital patient monitoring and tailored information have the potential to improve patient pathways, but knowledge about how these are experienced by patients is limited.
The goal is to find out if Norwegian trauma patients who receive tailored patient information and patient-managed outpatient digital follow-up, in addition to standard treatment have:
- Less disability
- Return more often to work
- Improved quality of life
The study population are Norwegian trauma patients, 16 years or older at date of inclusion, who are admitted to Haukeland University hospital (HUS) following trauma with trauma team activation. 256 patients will be included in this trial.
Participants will:
- Answer a questionnaire at inclusion, one month, 6 months and 12 months.
- Participants in the intervention group will be invited to digital outpatient follow up one month after the accident.
- Some participants will be interviewed about how they experienced their trauma follow up.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Trauma is the leading cause of death worldwide in patients aged 1-45 years. Injuries and violence contribute to approximately 10% of all disability-adjusted life years globally. In Norway, approximately 10,000 patients are admitted to hospital annually due to trauma, with 66% being male. The mean age is 43 years for male and 48 years for female, indicating a relatively young patient population compared to other medical cohorts. The socioeconomic and functional implications of trauma are significant. With the expected demographic shift toward an aging population in Norway, the incidence of trauma among older adults is also expected to increase, placing greater demands on in-hospital trauma and rehabilitation services. Socioeconomic status, gender and age have been identified as key predictors of long-term outcomes following trauma, with female and individuals with lower education levels or ongoing compensation claims often reporting poorer outcomes.
While mortality rates are decreasing due to advancements in trauma systems, prevention strategies and medical care, a significant proportion of trauma survivors experience longterm disabilities, reduced quality of life, and difficulties in returning to work. These consequences impose substantial burdens on individuals, families, and society. Considering these issues, a shift in focus is needed-from survival alone to long-term functional recovery and quality of life after trauma.
Severe trauma often requires long-term follow-up, both physically and psychosocially. Traditional follow-up is often fragmented and not tailored to individual needs. Digital patient monitoring and tailored information have the potential to improve patient pathways, but knowledge about how these are experienced by patients, relatives, and healthcare professionals is limited.
This study aims to investigate how early rehabilitation and patient-centred care pathways can improve short and long-term outcomes for trauma patients. The objectives of the POSTRAUMA-trial is to assess the efficacy of a tailored patient information and patient managed outpatient digital follow-up (I-POD), as an adjunct to standard treatment according to the national guidelines in the National Trauma Plan (NTP) among adult trauma patients in Norway. The main research question is whether participants in the intervention group have less disability and improved health-related quality of life 6 months after the accident compared to the control group which receives standard treatment alone?
The latter part of the trial is a qualitative study which will follow the consolidated criteria for reporting qualitative studies (COREQ). SI will through in-dept and semi-structured interviews explore the participants experiences following trauma in general, and more specific to evaluate how the written patient information and digital follow-up was perceived. The SI will encourage the participants to talk about issues regarding this by asking open-ended questions in one-to-one interviews. The illness trajectory framework will be used as a theoretical framework, along with the WHOs International Classification of Functioning, Disability and Health (ICF) to ensure that preinjury, physical and biopsychosocial factors are evaluated.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Marianne Wesnes, Cand. med.
- Telefonnummer: +47 996 20 649
- E-Mail: marianne.wesnes@helse-bergen.no
Studieren Sie die Kontaktsicherung
- Name: Geir Arne Sunde, Ph.d.
- Telefonnummer: +47 992 04 008
- E-Mail: geir.arne.sunde@helse-bergen.no
Studienorte
-
-
-
Bergen, Norwegen, 5021
- Surgical Department, Haukeland University hospital
-
Kontakt:
- Marianne Wesnes, Cand.med
- Telefonnummer: +47 996 20 649
- E-Mail: marianne.wesnes@helse-bergen.no
-
Kontakt:
- Geir Arne Sunde, Ph.d
- Telefonnummer: +47 992 04 008
- E-Mail: geir.arne.sunde@helse-bergen.no
-
Unterermittler:
- Marianne Wesnes, Cand.med
-
Hauptermittler:
- Geir Arne Sunde, Ph.d
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- 16 years or older
- Fulfils the national criteria for TTA and admitted to HUS following trauma
- Included in NTR database
- Able to give informed consent
Exclusion Criteria:
- 15 years or younger
- Not included in NTR database
- Deceased before discharge from the hospital.
- Not able to give informed consent
- Insufficient command of the Norwegian language
- Foreign tourists or nationals
- Suicide attempt or serious self-inflicted trauma
- Serious psychiatric disorders or serious ongoing substance abuse
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Kein Eingriff: Control group
Standard treatment and follow up after trauma according to national guidelines in the National trauma plan. |
|
|
Aktiver Komparator: Intervention group
Tailored patient information and patient-managed outpatient follow up as an adjunct to standard treatment according to national guidelines in the National trauma plan |
The objective of the POSTRAUMA-trial is to assess if the I-POD intervention combined with standard treatment according to national guidelines, lead to less disability measured by EQ5D-index, better health-related quality of life measured by EQ-VAS and increased return to studies and work compared to standard treatment after trauma.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
EuroQol five-dimension utility score (EQ5D-index) from baseline to 6 months after the trauma in both groups.
Zeitfenster: From baseline to 6 months after the trauma
|
The primary objective is to assess the efficacy of the I-POD-intervention as an adjunct to standard treatment after trauma according to national guidelines in adult patients in Norway. The efficacy is measured as the primary endpoint: EuroQol five-dimension utility score (EQ5D-index) from baseline to 6 months after the trauma in both groups. EQ5D-index ranges from - 0,59 (worst score) to 1 (perfect health, best score). 0 equals death. Baseline is defined as the time of inclusion. The I-POD intervention is a tailored patient Information and Patient-managed Outpatient Digital follow-up treatment. |
From baseline to 6 months after the trauma
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Unterschiede in der Rückkehr zur Arbeit (RTW) zwischen der Kontrollgruppe und der Interventionsgruppe nach 1 Monat, 6 Monaten und 12 Monaten nach dem Trauma anhand von patientenberichteten Daten nach 1 Monat sowie nach 6 und 12 Monaten anhand von NTR-Daten, gemessen mit dichotomen (ja/nein) Angaben
Zeitfenster: Baseline zu 1 Monat, 6 Monaten und 12 Monaten
|
Baseline zu 1 Monat, 6 Monaten und 12 Monaten
|
|
|
Differences in EuroQol five-dimension utility score (EQ5D-index) between the control group and the intervention group from baseline to 1 month and 12 months after the trauma.
Zeitfenster: Baseline to 1 month and 12 months after the trauma
|
EQ5D-index ranges from - 0,59 (worst score) to 1 (perfect health, best score). 0 equals death. |
Baseline to 1 month and 12 months after the trauma
|
|
Differences in HRQoL between the control group and the intervention group from baseline to 1 month, 6 months and 12 months after the trauma, measured by EuroQol visual analogue scale (EQ-VAS).
Zeitfenster: Baseline to 1 month, 6 months and 12 months after the trauma
|
The EQ-VAS (EuroQol Visual Analogue Scale) is a standard tool used with the EQ-5D health questionnaire to measure a person's self-rated overall health on a vertical scale from 0 (worst imaginable health) to 100 (best imaginable health). |
Baseline to 1 month, 6 months and 12 months after the trauma
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: Geir Arne Sunde, Ph.d, Haukeland University hospital, Surgical Department
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 909877
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Sharing of privacy data is not within the scope of the ethical approval granted by REK West.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .